SG11201807023QA - Compositions and methods for preventing and/or treating vitamin b12 deficiency - Google Patents
Compositions and methods for preventing and/or treating vitamin b12 deficiencyInfo
- Publication number
- SG11201807023QA SG11201807023QA SG11201807023QA SG11201807023QA SG11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- deficiency
- pct
- preventing
- treating vitamin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111110111010111111011101111101101111101111011111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/146580 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 35/74 (2015.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/NL2017/050119 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 27 February 2017 (27.02.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 2016323 25 February 2016 (25.02.2016) NL kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: (72) CAELUS PHARMACEUTICALS B.V. TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [NL/NL]; 50, Rondweg, 3474 KG Zegveld (NL). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Inventor: DE VOS, Willem Meindert; 77, Oude Ben- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, nekomseweg, 6717 LM Ede (NL). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (74) Agent: KINGMA, Rd.; P.O. Box 3241, 2280 GE Rijswijk GW, KM, ML, MR, NE, SN, TD, TG). (NL). Published: (81) Designated States (unless otherwise indicated, for every with international search report (Art. 21(3)) kind of national protection available): AE, AG, AL, AM, Il © GC ir) ,tD iv 1-1 IN 1-1 (54) Title: COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING VITAMIN B12 DEFICIENCY 0 N (57) : A method for preventing and/or treating vitamin B12 deficiency is taught. The method comprises administering a en. ) composition comprising pseudovitamin B12 producing bacteria, optionally in conjunction with mucin-degrading and/or propionate- producing bacteria, to a subject in need thereof. The method is particularly suitable for administration to subjects suffering from vit- amin B12 deficiency due to metformintreatment fortype-2 diabetes, and to subjects having undergone bariatric surgery.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2016323 | 2016-02-25 | ||
| PCT/NL2017/050119 WO2017146580A1 (en) | 2016-02-25 | 2017-02-27 | Compositions and methods for preventing and/or treating vitamin b12 deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807023QA true SG11201807023QA (en) | 2018-09-27 |
Family
ID=56507778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807023QA SG11201807023QA (en) | 2016-02-25 | 2017-02-27 | Compositions and methods for preventing and/or treating vitamin b12 deficiency |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10857189B2 (en) |
| EP (1) | EP3419637B1 (en) |
| JP (2) | JP7012651B2 (en) |
| KR (1) | KR20180113535A (en) |
| CN (1) | CN108697742A (en) |
| AU (1) | AU2017222990A1 (en) |
| BR (1) | BR112018017233A2 (en) |
| CA (1) | CA3014525A1 (en) |
| ES (1) | ES2865477T3 (en) |
| RU (1) | RU2730870C2 (en) |
| SG (1) | SG11201807023QA (en) |
| WO (1) | WO2017146580A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| JP7012651B2 (en) | 2016-02-25 | 2022-01-28 | カエルス ファーマシューティカルズ ビー．ヴィ． | Compositions and Methods for Preventing and / or Treating Vitamin B12 Deficiency |
| PT3443071T (en) * | 2016-04-11 | 2022-01-19 | Univ Wageningen | Novel bacterial species |
| EP3675882A4 (en) | 2017-08-30 | 2021-07-28 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| CA3106315A1 (en) * | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307026D0 (en) * | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| KR101982491B1 (en) | 2011-08-30 | 2019-05-27 | 아카데미쉬 메디쉬 센트륨 | Method for preventing and/or treating insulin resistance |
| CA2848520C (en) | 2011-09-29 | 2019-11-26 | Seattle Genetics, Inc. | Intact mass determination of protein conjugated agent compounds |
| US20140242654A1 (en) | 2013-02-26 | 2014-08-28 | Coskata, Inc. | Butyrate Producing Clostridium species, Clostridium pharus |
| WO2014150094A1 (en) | 2013-03-15 | 2014-09-25 | University Of Florida Research Foundation, Inc. | Butyrogenic bacteria as probiotics to treat clostridium difficile |
| KR101470995B1 (en) * | 2013-08-30 | 2014-12-09 | 주식회사 바이오리쏘스 | Propionic acid producing microorganism and roughage comprising the same |
| SG11201705450SA (en) | 2015-01-09 | 2017-07-28 | Univ Wageningen | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases |
| EP3397748B1 (en) | 2015-12-31 | 2021-03-03 | Caelus Pharmaceuticals B.V. | Method for culturing and preserving eubacterium hallii |
| JP7012651B2 (en) | 2016-02-25 | 2022-01-28 | カエルス ファーマシューティカルズ ビー．ヴィ． | Compositions and Methods for Preventing and / or Treating Vitamin B12 Deficiency |
-
2017
- 2017-02-27 JP JP2018541399A patent/JP7012651B2/en active Active
- 2017-02-27 CN CN201780013478.XA patent/CN108697742A/en active Pending
- 2017-02-27 WO PCT/NL2017/050119 patent/WO2017146580A1/en active Application Filing
- 2017-02-27 BR BR112018017233A patent/BR112018017233A2/en not_active IP Right Cessation
- 2017-02-27 AU AU2017222990A patent/AU2017222990A1/en not_active Abandoned
- 2017-02-27 ES ES17715799T patent/ES2865477T3/en active Active
- 2017-02-27 EP EP17715799.7A patent/EP3419637B1/en active Active
- 2017-02-27 SG SG11201807023QA patent/SG11201807023QA/en unknown
- 2017-02-27 CA CA3014525A patent/CA3014525A1/en not_active Abandoned
- 2017-02-27 US US16/075,073 patent/US10857189B2/en active Active
- 2017-02-27 KR KR1020187023684A patent/KR20180113535A/en unknown
- 2017-02-27 RU RU2018133333A patent/RU2730870C2/en active
-
2021
- 2021-11-26 JP JP2021191752A patent/JP7219801B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190038678A1 (en) | 2019-02-07 |
| JP2022031800A (en) | 2022-02-22 |
| JP7012651B2 (en) | 2022-01-28 |
| CA3014525A1 (en) | 2017-08-31 |
| RU2018133333A3 (en) | 2020-03-25 |
| WO2017146580A1 (en) | 2017-08-31 |
| KR20180113535A (en) | 2018-10-16 |
| RU2730870C2 (en) | 2020-08-26 |
| AU2017222990A1 (en) | 2018-09-20 |
| JP2019506413A (en) | 2019-03-07 |
| BR112018017233A2 (en) | 2019-01-15 |
| CN108697742A (en) | 2018-10-23 |
| EP3419637A1 (en) | 2019-01-02 |
| US10857189B2 (en) | 2020-12-08 |
| ES2865477T3 (en) | 2021-10-15 |
| JP7219801B2 (en) | 2023-02-08 |
| RU2018133333A (en) | 2020-03-25 |
| EP3419637B1 (en) | 2021-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807023QA (en) | Compositions and methods for preventing and/or treating vitamin b12 deficiency | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |